Since 1985, ONY Biotech has been at the forefront of developing critical therapies for premature and critically ill infants. Our unwavering mission is to improve outcomes for these vulnerable newborns and support the families who care for them. Our flagship product, Infasurf® (calfactant), is a trusted treatment for respiratory distress syndrome (RDS) in premature infants. Expanding our commitment to neonatal care, we now offer AerVia®, a neonatal supraglottic airway device designed to support safe, effective airway management. As a U.S.-based biotechnology company, ONY Biotech proudly delivers innovative solutions that serve NICUs across the country and around the world. Every day, we push forward in our commitment to discover the next breakthrough in infant respiratory health. To learn more, visit www.onybiotech.com, or call us at 877.274.4669.